Citation Impact
Citing Papers
Place of Cabergoline in Acromegaly: A Meta-Analysis
2011
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
2009
Acromegaly
2006 Standout
Pegvisomant and cabergoline combination therapy in acromegaly
2012
Psychedelics
2016 Standout
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
2014
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
1998
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
1998 Standout
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development
1995
Acromegaly
1994
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Diagnosis and Complications of Cushing’s Syndrome: A Consensus Statement
2003 Standout
Pharmacologic properties of (?)-3PPP (preclamol) in man
1992 StandoutNobel
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
2004
Effect of ingestion of glucose on GH and TSH secretion: Evidence for stimulation of somatostatin release from the hypothalamus by acute hyperglycemia in normal man and its impairment in acromegalic patients
1989
Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: Resistance to differential rearing conditions
1991 Standout
Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly
1995
ACROMEGALY
1987
In Vitro Effect of Dopamine and L-Dopa on Prolactin and Growth Hormone Release from Human Pituitary Adenomas*
1979
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
Pathophysiology of Acromegaly*
1983
Abnormal Plasma Catecholamine Responses in Acromegalics
1979
The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone
1983
Treatment of Acromegaly with Dopamine Agonists
1992
AN ASSESSMENT OF GLUCOSE INTOLERANCE IN ACROMEGALY AND ITS RESPONSE TO MEDICAL TREATMENT
1980
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
The effects of putative 5-hydroxytryptamine receptor active agents ond-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesion
1984
Effects of a new type of 5-HT receptor agonist on male rat sexual behavior
1981 StandoutNobel
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
1995
Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand
2003
Endocrine profile of ergot alkaloids
1977
On the Mode of the Prolactin Release-Inhibiting Action of the Serotonin Receptor Blockers Metergoline, Methysergide, and Cyproheptadine*
1981
A Pregnancy in an Acromegalic Woman during Bromocriptine Treatment: Effects on Growth Hormone and Prolactin in the Maternal, Fetal, and Amniotic Compartments*
1979
Advances in the Treatment of Prolactinomas
2006
Prolactin-Lowering and -Releasing Drugs Mechanisms of Action and Therapeutic Applications
1983
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity
1985 StandoutNobel
Role of Dopamine in the Regulation of Growth Hormone Secretion: Dopamine and Bromocriptine Augment Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Normal Man
1987
Bromocriptine
1977
8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity
1982 StandoutNobel
Bromocriptine
1979
Acromegaly: historical perspectives and current therapy
2001
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
2016 Standout
Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity II. Theoretical considerations
1985 StandoutNobel
Neuropharmacologic control of neuroendocrine function in man
1975
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
1987 StandoutScience
Response of central monoaminergic neurons to lisuride: Comparison with LSD
1979
Hallucinogens
2004 Standout
Works of L Botalla being referenced
Lisuride Hydrogen Maleate: Evidence for a Long Lasting Dopaminergic Activity in Humans
1978
Effects of Nomifensine on Growth Hormone and Prolactin Secretion in Normal Subjects and in Pathological Hyperprolactinemia*
1982
Stable Reduction of Plasma Growth Hormone (hGH) Levels During Chronic Administration of 2-Br-α-ergocryptine (CB-154) in Acromegalic Patients
1975
INHIBITORY EFFECT OF L-DOPA ON GH RELEASE IN ACROMEGALIC PATIENTS1
1972
Inhibitory Effect of Dopaminergic Stimulation on GH Release in Acromegaly
1974
DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION1
1974
Growth Hormone (GH)-Releasing Activity of TRH and GH-Lowering Effect of Dopaminergic Drugs in Acromegaly: Homogeneity in the Two Responses
1974
EVIDENCE FOR A DOPAMINERGIC ACTIVITY OF METHYSERGIDE IN HUMANS
1977
Effectiveness.of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states
1980
Inhibitory Effect of an Ergoline Derivative, Methergoline, on Growth Hormone and Prolactin Levels in Acromegalic Patients
1976
EFFECT OF DOPAMINE INFUSION ON PLASMA LEVELS OF GROWTH HORMONE IN NONMAL SUBJECTS AND IN AGROMEGALIC PATIENTS
1976